JP2007517067A - スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤 - Google Patents

スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤 Download PDF

Info

Publication number
JP2007517067A
JP2007517067A JP2006547613A JP2006547613A JP2007517067A JP 2007517067 A JP2007517067 A JP 2007517067A JP 2006547613 A JP2006547613 A JP 2006547613A JP 2006547613 A JP2006547613 A JP 2006547613A JP 2007517067 A JP2007517067 A JP 2007517067A
Authority
JP
Japan
Prior art keywords
formulation
sae
corticosteroid
solution
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006547613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517067A5 (https=
Inventor
ジェイムズ・ディー・ピプキン
ルーパート・オー・ツィマーラー
ダイアン・オー・トムプソン
ジェロルド・エル・モーシャー
Original Assignee
サイデックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイデックス・インコーポレイテッド filed Critical サイデックス・インコーポレイテッド
Publication of JP2007517067A publication Critical patent/JP2007517067A/ja
Publication of JP2007517067A5 publication Critical patent/JP2007517067A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nanotechnology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006547613A 2003-12-31 2004-12-31 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤 Withdrawn JP2007517067A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53362803P 2003-12-31 2003-12-31
PCT/US2005/000082 WO2005065435A2 (en) 2003-12-31 2004-12-31 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012184694A Division JP5782413B2 (ja) 2003-12-31 2012-08-24 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤

Publications (2)

Publication Number Publication Date
JP2007517067A true JP2007517067A (ja) 2007-06-28
JP2007517067A5 JP2007517067A5 (https=) 2008-01-31

Family

ID=34794240

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2006547613A Withdrawn JP2007517067A (ja) 2003-12-31 2004-12-31 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2006547614A Abandoned JP2007517068A (ja) 2003-12-31 2004-12-31 単位用量懸濁液から調製されるスルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2006547615A Abandoned JP2007517069A (ja) 2003-12-31 2004-12-31 スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2012184694A Expired - Lifetime JP5782413B2 (ja) 2003-12-31 2012-08-24 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2015041915A Pending JP2015129173A (ja) 2003-12-31 2015-03-04 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2016133094A Expired - Lifetime JP6186478B2 (ja) 2003-12-31 2016-07-05 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2006547614A Abandoned JP2007517068A (ja) 2003-12-31 2004-12-31 単位用量懸濁液から調製されるスルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2006547615A Abandoned JP2007517069A (ja) 2003-12-31 2004-12-31 スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2012184694A Expired - Lifetime JP5782413B2 (ja) 2003-12-31 2012-08-24 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2015041915A Pending JP2015129173A (ja) 2003-12-31 2015-03-04 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
JP2016133094A Expired - Lifetime JP6186478B2 (ja) 2003-12-31 2016-07-05 スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤

Country Status (15)

Country Link
EP (4) EP1729724A4 (https=)
JP (6) JP2007517067A (https=)
KR (3) KR20070005586A (https=)
CN (3) CN1921834A (https=)
AU (3) AU2004311478A1 (https=)
BR (3) BRPI0418276B8 (https=)
CA (3) CA2551749C (https=)
DK (1) DK1732512T3 (https=)
HU (1) HUE032527T2 (https=)
IL (6) IL176575A0 (https=)
MX (2) MX348041B (https=)
NZ (1) NZ548225A (https=)
PT (1) PT1732512T (https=)
RU (3) RU2006127432A (https=)
WO (3) WO2005065435A2 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516873A (ja) * 2009-02-04 2012-07-26 アクティファエロ ゲーエムベーハー リサーチ アンド デベロップメント 重度で抑制されていないぜんそくの治療方法、装置、および組成物
JP2012530708A (ja) * 2009-06-18 2012-12-06 アラーガン インコーポレイテッド 安全なデスモプレシン投与
JP2017509709A (ja) * 2014-03-28 2017-04-06 ユニベルシテ・ド・リエージュＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｉｅｇｅ シクロデキストリン及びブデソニド誘導体組成物ならびに方法
JP2018521987A (ja) * 2015-06-18 2018-08-09 セージ セラピューティクス， インコーポレイテッド 神経活性ステロイド溶液およびその使用方法
JP2020100658A (ja) * 2014-03-28 2020-07-02 ユニベルシテ・ド・リエージュＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｉｅｇｅ シクロデキストリン及びブデソニド誘導体組成物ならびに方法
JP2023517760A (ja) * 2020-03-19 2023-04-26 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション シクロデキストリン複合体としての化合物の安定化
JP2023518269A (ja) * 2020-03-18 2023-04-28 メモリアル スローン ケタリング キャンサー センター Ｃｏｖｉｄ－１９のための吸入療法

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
PL2708225T3 (pl) 2004-04-23 2019-07-31 Cydex Pharmaceuticals, Inc. Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
DK1945228T4 (da) * 2005-10-26 2015-01-12 Cydex Pharmaceuticals Inc Sulfoalkyl-ether-cyclodextrin-sammensætninger og fremgangsmåder til fremstilling deraf
RU2453556C2 (ru) 2005-11-09 2012-06-20 Протеоликс, Инк. Соединения для ингибирования фермента
WO2007059507A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions comprising lipoxygenase inhibitors and cyclodextrin
EP1959953A2 (en) * 2005-12-02 2008-08-27 Alembic Limited Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
JP2009520823A (ja) * 2005-12-20 2009-05-28 ティカ レーケメデル アーベー 薬物動態学的プロフィールの向上を有するコルチコステロイドを送達するための方法およびシステム
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
ES2671342T3 (es) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Antibióticos nebulizados para terapia de inhalación
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
PT2010220T (pt) * 2006-04-03 2022-05-20 Ceva Animal Health Pty Ltd Formulações de polisulfato de pentosano estabilizado (pps)
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1894559A1 (en) * 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
US20090325917A1 (en) * 2006-10-19 2009-12-31 Cipla Limited Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
WO2008065142A1 (en) * 2006-11-29 2008-06-05 N.V. Organon Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
KR20170040374A (ko) 2007-10-04 2017-04-12 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
WO2009062193A2 (en) * 2007-11-09 2009-05-14 Map Pharmaceuticals, Inc. Methods for administering corticosteroid formulations
RU2363473C1 (ru) * 2008-02-18 2009-08-10 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ антифлогистической активации в эксперименте
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010097700A1 (en) * 2009-02-25 2010-09-02 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
WO2010132711A1 (en) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RU2445119C2 (ru) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Фармацевтическая композиция и способ ее ингаляционного введения
CN102188371B (zh) * 2011-05-11 2013-01-23 台州职业技术学院 一种环索奈德纳米粒水溶液及其制备方法
CN102973574A (zh) * 2011-09-02 2013-03-20 北京燕锋晨医药技术发展有限公司 一种用于治疗哮喘的药物组合物及制备方法
AU2013259872B2 (en) 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR20200130748A (ko) * 2012-05-08 2020-11-19 오닉스 세라퓨틱스, 인크. 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
RU2506080C1 (ru) * 2012-09-25 2014-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО НижГМА Минздравсоцразвития России) Способ лечения и профилактики осложнений в полости рта, вызванных приемом ингаляционных гормональных препаратов у больных бронхиальной астмой
RU2493827C1 (ru) * 2012-10-03 2013-09-27 Шолекс Девелопмент Гмбх Стабильный комбинированный раствор фенотерола гидробромида и ипратропия бромида
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP3256216B1 (en) * 2015-02-13 2023-09-06 Vanderbilt University Milrinone composition and method for administering same
WO2017193110A1 (en) * 2016-05-06 2017-11-09 Stites Adam Cannabinoid compositions for sublingual spray nebulizer
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2019147154A1 (ru) * 2018-01-23 2019-08-01 Александр Григорьевич ЧУЧАЛИН Фармацевтическая композиция (варианты) применение фармацевтической композиции (варианты)
KR102891439B1 (ko) 2019-08-01 2025-11-25 인카다 테라퓨틱스, 인크. 항부정맥 제제
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021262648A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol and budesonide
US20210393521A1 (en) * 2020-06-23 2021-12-23 Cai Gu Huang Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
CN113018280A (zh) * 2021-03-01 2021-06-25 石家庄四药有限公司 一种异丙托溴铵吸入用溶液制剂及其制备方法
CN121466042A (zh) * 2026-01-09 2026-02-06 苏州市立医院 一种吸入用药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504783A (ja) * 1990-01-23 1993-07-22 ザ ユニバーシティ オブ カンザス 水溶解性の高いシクロデキストリン誘導体組成物及びその用途
JPH06511513A (ja) * 1992-07-27 1994-12-22 ザ　ユニヴァシティ　オブ　カンサス 水溶性の高いシクロデキストリン誘導体及びその使用
US6358935B1 (en) * 1998-09-02 2002-03-19 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
WO2003080079A1 (en) * 2002-03-19 2003-10-02 Cydex, Inc. Use of sulfoalkyl ether cyclodextrin as a preservative

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008875A (en) * 1960-01-08 1961-11-14 Upjohn Co Neomycin and mirystyl-gamma-picolinium halide compositions
BE629985A (https=) * 1962-11-29
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5510339A (en) 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
CA2206657C (en) 1994-12-22 2009-05-19 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, pth
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
EP0934341A1 (en) * 1996-10-28 1999-08-11 Farmac Nederland B.V. Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
DE29923847U1 (de) * 1998-05-27 2001-04-12 Euroceltique S.A., Luxemburg/Luxembourg Präparate zur Anwendung von entzündungshemmenden, insbesondere antiseptischen Wirkstoffen und/oder die Wundheilung fördernden Wirkstoffen in den unteren Atemwegen
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
FR2789685B1 (fr) 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
WO2001085218A2 (en) 2000-05-11 2001-11-15 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
DE60211132T2 (de) 2001-02-14 2006-09-28 Akzo Nobel N.V. 2-alkylierte cyclodextrin-derivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2003070194A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Amino acid and peptide-modified forms of glucocorticoids
WO2004032862A2 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504783A (ja) * 1990-01-23 1993-07-22 ザ ユニバーシティ オブ カンザス 水溶解性の高いシクロデキストリン誘導体組成物及びその用途
JPH06511513A (ja) * 1992-07-27 1994-12-22 ザ　ユニヴァシティ　オブ　カンサス 水溶性の高いシクロデキストリン誘導体及びその使用
US6358935B1 (en) * 1998-09-02 2002-03-19 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
WO2003080079A1 (en) * 2002-03-19 2003-10-02 Cydex, Inc. Use of sulfoalkyl ether cyclodextrin as a preservative

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012516873A (ja) * 2009-02-04 2012-07-26 アクティファエロ ゲーエムベーハー リサーチ アンド デベロップメント 重度で抑制されていないぜんそくの治療方法、装置、および組成物
US11419914B2 (en) 2009-06-18 2022-08-23 Serenity Pharmaceuticals Llc Safe desmopressin administration
JP2012530708A (ja) * 2009-06-18 2012-12-06 アラーガン インコーポレイテッド 安全なデスモプレシン投与
US9539302B2 (en) 2009-06-18 2017-01-10 Allergan, Inc. Safe desmopressin administration
US12090190B2 (en) 2009-06-18 2024-09-17 Acerus Pharmaceuticals USA, LLC Safe desmopressin administration
JP2017509709A (ja) * 2014-03-28 2017-04-06 ユニベルシテ・ド・リエージュＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｉｅｇｅ シクロデキストリン及びブデソニド誘導体組成物ならびに方法
JP2020100658A (ja) * 2014-03-28 2020-07-02 ユニベルシテ・ド・リエージュＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｌｉｅｇｅ シクロデキストリン及びブデソニド誘導体組成物ならびに方法
JP7008097B2 (ja) 2014-03-28 2022-02-10 ユニベルシテ・ド・リエージュ シクロデキストリン及びブデソニド誘導体組成物ならびに方法
JP2021127350A (ja) * 2015-06-18 2021-09-02 セージ セラピューティクス， インコーポレイテッド 神経活性ステロイド溶液およびその使用方法
JP7374954B2 (ja) 2015-06-18 2023-11-07 セージ セラピューティクス， インコーポレイテッド 神経活性ステロイド溶液およびその使用方法
JP2018521987A (ja) * 2015-06-18 2018-08-09 セージ セラピューティクス， インコーポレイテッド 神経活性ステロイド溶液およびその使用方法
JP2023518269A (ja) * 2020-03-18 2023-04-28 メモリアル スローン ケタリング キャンサー センター Ｃｏｖｉｄ－１９のための吸入療法
JP2023517760A (ja) * 2020-03-19 2023-04-26 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション シクロデキストリン複合体としての化合物の安定化

Also Published As

Publication number Publication date
WO2005065651A1 (en) 2005-07-21
KR20070005586A (ko) 2007-01-10
CA2551749C (en) 2014-02-11
EP1718276A4 (en) 2008-07-23
JP2015129173A (ja) 2015-07-16
IL225946A0 (en) 2013-06-27
BRPI0418276B1 (pt) 2017-02-14
EP1729724A4 (en) 2008-07-23
JP2016172774A (ja) 2016-09-29
KR20070007075A (ko) 2007-01-12
JP2007517069A (ja) 2007-06-28
EP1732512B1 (en) 2017-03-22
CN1921834A (zh) 2007-02-28
EP3238708A1 (en) 2017-11-01
CA2551749A1 (en) 2005-07-21
CN1976679B (zh) 2011-08-31
JP2007517068A (ja) 2007-06-28
AU2004312095A1 (en) 2005-07-21
NZ548225A (en) 2012-12-21
PT1732512T (pt) 2017-07-24
JP2012224648A (ja) 2012-11-15
WO2005065435A3 (en) 2005-09-01
CN1976679A (zh) 2007-06-06
WO2005065435A2 (en) 2005-07-21
IL176575A0 (en) 2006-10-31
BRPI0418386A (pt) 2007-05-22
IL251496B (en) 2021-04-29
CA2551826A1 (en) 2005-07-21
HUE032527T2 (en) 2017-09-28
RU2006127467A (ru) 2008-02-10
IL176576A0 (en) 2006-10-31
KR20070007076A (ko) 2007-01-12
AU2004311478A1 (en) 2005-07-21
DK1732512T3 (en) 2017-07-10
JP5782413B2 (ja) 2015-09-24
BRPI0418276B8 (pt) 2021-05-25
CA2552641A1 (en) 2005-07-21
IL251496A0 (en) 2017-05-29
IL176577A0 (en) 2006-10-31
EP1732512A2 (en) 2006-12-20
WO2005065649A1 (en) 2005-07-21
MXPA06007581A (es) 2007-03-09
EP1729724A1 (en) 2006-12-13
RU2388462C2 (ru) 2010-05-10
EP1718276A2 (en) 2006-11-08
AU2004312096A1 (en) 2005-07-21
RU2006127432A (ru) 2008-02-10
BRPI0418232A (pt) 2007-04-27
MX348041B (es) 2017-05-25
EP1732512A4 (en) 2008-07-23
JP6186478B2 (ja) 2017-08-23
CN1921830A (zh) 2007-02-28
IL225946A (en) 2017-04-30
RU2390330C2 (ru) 2010-05-27
BRPI0418276A (pt) 2007-05-02
RU2006127443A (ru) 2008-02-10

Similar Documents

Publication Publication Date Title
JP6186478B2 (ja) スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
US10799599B2 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020298A1 (en) Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
AU2014227557B2 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MXPA06007583A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120824

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120910

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140224

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140905

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140905